SEARCH:   Advanced

Blood, 1 August 2004, Vol. 104, No. 3, pp. 634-641. Prepublished online as a Blood First Edition Paper on March 11, 2004; DOI 10.1182/blood-2003-06-2095. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-06-2095v1 104/3/634    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Pfreundschuh, M. Articles by the German High-Grade Non-Hodgkin's Lymphoma Study Group, Search for Related Content PubMed PubMed Citation Articles by Pfreundschuh, M. Articles by the German High-Grade Non-Hodgkin's Lymphoma Study Group, Related Collections Neoplasia Free Research Articles Clinical Trials and Observations Related Article in Blood Online Related Letter in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL Michael Pfreundschuh, Lorenz Trümper, Marita Kloess, Rudolf Schmits, Alfred C. Feller, Christian Rübe, Christian Rudolph, Marcel Reiser, Dieter K. Hossfeld, Hartmut Eimermacher, Dirk Hasenclever, Norbert Schmitz, Markus Loeffler, and the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) From the Saarland University Medical School, Homburg/Saar, Germany; Universitätsklinikum Göttingen, Göttingen, Germany; Institut für Medizinische Informatik, Statistik und Epidemiologie (IMISE) Universität Leipzig, Leipzig, Germany; Institut für Pathologie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Germany; Klinikum Cottbus, Cottbus, Germany; Med Klinik der Universität zu Köln, Köln, Germany; Universitätsklinikum Eppendorf, Hamburg, Germany; St Marien-Hospital Hagen, Hagen, Germany; and Krankenhaus St Georg, Hamburg, Germany. Cyclophosphamide, doxorubicin, vincristine, and prednisone, given every 3 weeks (CHOP-21), is standard chemotherapy for aggressive lymphomas. To determine whether biweekly CHOP (CHOP-14) with or without etoposide is more effective than CHOP-21, 689 patients ages 61 to 75 years were randomized to 6 cycles of CHOP-21, CHOP-14, CHOEP-21 (CHOP plus etoposide 100 mg/m2 days 1-3), or CHOEP-14. Patients in the 2-weekly regimens received granulocyte colony-stimulating factor (G-CSF) starting from day 4. Patients received radiotherapy (36 Gy) to sites of initial bulky disease and extranodal disease. Complete remission rates were 60.1% (CHOP-21), 70.0% (CHOEP-21), 76.1% (CHOP-14), and 71.6% (CHOEP-14). Five-year event-free and overall survival rates were 32.5% and 40.6%, respectively, for CHOP-21 and 43.8% and 53.3%, respectively, for CHOP-14. In a multivariate analysis, the relative risk reduction was 0.66 (P = .003) for event-free and 0.58 (P < .001) for overall survival after CHOP-14 compared with CHOP-21. Toxicity of CHOP-14 and CHOP-21 was similar, but CHOEP-21 and in particular CHOEP-14 were more toxic. Due to its favorable efficacy and toxicity profile, CHOP-14 should be considered the new standard chemotherapy regimen for patients ages 60 or older with aggressive lymphoma. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Is more better? David Linch Blood 2004 104: 596-597. [Full Text] [PDF] Related Letter in Blood Online: Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma Bertrand Coiffier, Gilles Salles, Michael Pfreundschuh, and Markus Loeffler Blood 2004 104: 1584-1586. [Full Text] [PDF] This article has been cited by other articles: H.-W. Bernd, M. Ziepert, C. Thorns, W. Klapper, H.-H. Wacker, M. Hummel, H. Stein, M.-L. Hansmann, G. Ott, A. Rosenwald, et al. Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials Haematologica, November 1, 2009; 94(11): 1569 - 1580. [Abstract] [Full Text] [PDF] H.A. Azim, L. Santoro, R.G. Bociek, S. Gandini, R.A. Malek, and H.A. Azim Jr High dose intensity doxorubicin in aggressive non-Hodgkin's lymphoma: a literature-based meta-analysis Ann. Onc., October 22, 2009; (2009) mdp425v1. [Abstract] [Full Text] [PDF] K. J. Savage, N. A. Johnson, S. Ben-Neriah, J. M. Connors, L. H. Sehn, P. Farinha, D. E. Horsman, and R. D. Gascoyne MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy Blood, October 22, 2009; 114(17): 3533 - 3537. [Abstract] [Full Text] [PDF] C. Laurent, C. Do, R. D. Gascoyne, L. Lamant, L. Ysebaert, G. Laurent, G. Delsol, and P. Brousset Anaplastic Lymphoma Kinase-Positive Diffuse Large B-Cell Lymphoma: A Rare Clinicopathologic Entity With Poor Prognosis J. Clin. Oncol., September 1, 2009; 27(25): 4211 - 4216. [Abstract] [Full Text] [PDF] E. Brusamolino First-line therapy of CD20+ diffuse large B-cell lymphoma: facts and open questions Haematologica, September 1, 2009; 94(9): 1194 - 1198. [Full Text] [PDF] N. Schoof, F. von Bonin, S. Zeynalova, M. Ziepert, W. Jung, M. Loeffler, M. Pfreundschuh, L. Trumper, and D. Kube Favorable impact of the interleukin-4 receptor allelic variant I75 on the survival of diffuse large B-cell lymphoma patients demonstrated in a large prospective clinical trial Ann. Onc., September 1, 2009; 20(9): 1548 - 1554. [Abstract] [Full Text] [PDF] C. Haioun, N. Mounier, J. F. Emile, D. Ranta, B. Coiffier, H. Tilly, C. Recher, C. Ferme, J. Gabarre, R. Herbrecht, et al. Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma Ann. Onc., June 30, 2009; (2009) mdp237v1. [Abstract] [Full Text] [PDF] H. Tilly, M. Dreyling, and On behalf of the ESMO Guidelines Working Group Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann. Onc., May 1, 2009; 20(suppl_4): iv110 - iv112. [Full Text] [PDF] V. Boehme, N. Schmitz, S. Zeynalova, M. Loeffler, and M. Pfreundschuh CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) Blood, April 23, 2009; 113(17): 3896 - 3902. [Abstract] [Full Text] [PDF] D. O'Mahony, J. C. Morris, M. Stetler-Stevenson, H. Matthews, M. R. Brown, T. Fleisher, S. Pittaluga, M. Raffeld, P. S. Albert, D. Reitsma, et al. EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies Clin. Cancer Res., April 1, 2009; 15(7): 2514 - 2522. [Abstract] [Full Text] [PDF] E. Jantunen, C. Canals, A. Rambaldi, G. Ossenkoppele, B. Allione, D. Blaise, E. Conde, H. Tilly, G. Cook, F. Clark, et al. Autologous stem cell transplantation in elderly patients (>=60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry Haematologica, December 1, 2008; 93(12): 1837 - 1842. [Abstract] [Full Text] [PDF] D. Kube, T.-D. Hua, F. von Bonin, N. Schoof, S. Zeynalova, M. Kloss, D. Gocht, B. Potthoff, M. Tzvetkov, J. Brockmoller, et al. Effect of Interleukin-10 Gene Polymorphisms on Clinical Outcome of Patients with Aggressive Non-Hodgkin's Lymphoma: An Exploratory Study Clin. Cancer Res., June 15, 2008; 14(12): 3777 - 3784. [Abstract] [Full Text] [PDF] M. Ziepert, R. Schmits, L. Trumper, M. Pfreundschuh, M. Loeffler, and On behalf of the German High-Grade Non-Hodgkin's L Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin's lymphoma Ann. Onc., April 1, 2008; 19(4): 752 - 762. [Abstract] [Full Text] [PDF] M. Pfreundschuh, C. Zwick, S. Zeynalova, U. Duhrsen, K.-H. Pfluger, T. Vrieling, R. Mesters, H.-G. Mergenthaler, H. Einsele, M. Bentz, et al. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) Ann. Onc., March 1, 2008; 19(3): 545 - 552. [Abstract] [Full Text] [PDF] K. Tsukasaki, A. Utsunomiya, H. Fukuda, T. Shibata, T. Fukushima, Y. Takatsuka, S. Ikeda, M. Masuda, H. Nagoshi, R. Ueda, et al. VCAP-AMP-VECP Compared With Biweekly CHOP for Adult T-Cell Leukemia-Lymphoma: Japan Clinical Oncology Group Study JCOG9801 J. Clin. Oncol., December 1, 2007; 25(34): 5458 - 5464. [Abstract] [Full Text] [PDF] L. Balducci, H. Al-Halawani, V. Charu, J. Tam, S. Shahin, L. Dreiling, and W. B. Ershler Elderly Cancer Patients Receiving Chemotherapy Benefit from First-Cycle Pegfilgrastim Oncologist, December 1, 2007; 12(12): 1416 - 1424. [Abstract] [Full Text] [PDF] C. H. Moskowitz, P. A. Hamlin, J. Gabrilove, J. R. Bertino, C. S. Portlock, D. J. Straus, A. N. Gencarelli, S. D. Nimer, and A. D. Zelenetz Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma Ann. Onc., November 1, 2007; 18(11): 1842 - 1850. [Abstract] [Full Text] [PDF] M. Cuadros, S. S. Dave, E. S. Jaffe, E. Honrado, R. Milne, J. Alves, J. Rodriguez, M. Zajac, J. Benitez, L. M. Staudt, et al. Identification of a Proliferation Signature Related to Survival in Nodal Peripheral T-Cell Lymphomas J. Clin. Oncol., August 1, 2007; 25(22): 3321 - 3329. [Abstract] [Full Text] [PDF] N. M. Kuderer, D. C. Dale, J. Crawford, and G. H. Lyman Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systematic Review J. Clin. Oncol., July 20, 2007; 25(21): 3158 - 3167. [Abstract] [Full Text] [PDF] J. O. Armitage How I treat patients with diffuse large B-cell lymphoma Blood, July 1, 2007; 110(1): 29 - 36. [Full Text] [PDF] M Bjorkholm, H Hagberg, H Holte, S Kvaloy, L Teerenhovi, H Anderson, E Cavallin-Stahl, J Myhre, H Pertovaara, A Ost, et al. Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up Ann. Onc., June 1, 2007; 18(6): 1085 - 1089. [Abstract] [Full Text] [PDF] C. Thieblemont and B. Coiffier Lymphoma in Older Patients J. Clin. Oncol., May 10, 2007; 25(14): 1916 - 1923. [Abstract] [Full Text] [PDF] L. F. Verdonck, A. Notenboom, D. D. de Jong, M. A. MacKenzie, G. E. G. Verhoef, M. H. H. Kramer, G. J. Ossenkoppele, J. K. Doorduijn, P. Sonneveld, and G. W. van Imhoff Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) Blood, April 1, 2007; 109(7): 2759 - 2766. [Abstract] [Full Text] [PDF] A. Kolstad, H. Holte, A. Fossa, G. F. Lauritzsen, P. Gaustad, and D. Torfoss Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen Haematologica, January 1, 2007; 92(1): 139 - 140. [Abstract] [Full Text] [PDF] V Boehme, S Zeynalova, M Kloess, M Loeffler, U Kaiser, M Pfreundschuh, and N Schmitz Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) Ann. Onc., January 1, 2007; 18(1): 149 - 157. [Abstract] [Full Text] [PDF] T. M. Habermann Antibody Therapy in Aggressive Lymphomas Hematology, January 1, 2007; 2007(1): 257 - 264. [Abstract] [Full Text] [PDF] T. J. Smith, J. Khatcheressian, G. H. Lyman, H. Ozer, J. O. Armitage, L. Balducci, C. L. Bennett, S. B. Cantor, J. Crawford, S. J. Cross, et al. 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline J. Clin. Oncol., July 1, 2006; 24(19): 3187 - 3205. [Abstract] [Full Text] [PDF] T. M. Habermann, E. A. Weller, V. A. Morrison, R. D. Gascoyne, P. A. Cassileth, J. B. Cohn, S. R. Dakhil, B. Woda, R. I. Fisher, B. A. Peterson, et al. Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma J. Clin. Oncol., July 1, 2006; 24(19): 3121 - 3127. [Abstract] [Full Text] [PDF] C. Dang and C. Hudis Can Granulocyte-Colony Stimulating Factor Worsen Anemia? J. Clin. Oncol., July 1, 2006; 24(19): 2985 - 2986. [Full Text] [PDF] D. A. Stewart, N. Bahlis, K. Valentine, A. Balogh, L. Savoie, D. G. Morris, A. Jones, C. Brown, and J. A. Russell Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma Blood, June 15, 2006; 107(12): 4623 - 4627. [Abstract] [Full Text] [PDF] M. Hummel, S. Bentink, H. Berger, W. Klapper, S. Wessendorf, T. F.E. Barth, H.-W. Bernd, S. B. Cogliatti, J. Dierlamm, A. C. Feller, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N. Engl. J. Med., June 8, 2006; 354(23): 2419 - 2430. [Abstract] [Full Text] [PDF] O. Bairey, O. Benjamini, D. Blickstein, A. Elis, and R. Ruchlemer Non-Hodgkin's lymphoma in patients 80 years of age or older Ann. Onc., June 1, 2006; 17(6): 928 - 934. [Abstract] [Full Text] [PDF] I. Oschlies, W. Klapper, M. Zimmermann, M. Krams, H.-H. Wacker, B. Burkhardt, L. Harder, R. Siebert, A. Reiter, and R. Parwaresch Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial Blood, May 15, 2006; 107(10): 4047 - 4052. [Abstract] [Full Text] [PDF] P. G. Gobbi, C. Broglia, F. Valentino, C. Mammi, M. Lombardo, F. Merli, S. Luminari, G. Polimeno, A. Riezzo, P. Lambelet, et al. The role of dose size in a chemotherapy regimen (ProMECE-CytaBOM) for the first-line treatment of large B-cell lymphomas: a randomized trial by the Gruppo Italiano Studio Linfomi (GISL) Ann. Onc., April 1, 2006; 17(4): 676 - 682. [Abstract] [Full Text] [PDF] J. S. Abramson T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis, and management. Oncologist, April 1, 2006; 11(4): 384 - 392. [Abstract] [Full Text] [PDF] M. A. Dawson, J. Mariani, A. Taylor, G. Koulouris, and S. Avery The successful treatment of primary cardiac lymphoma with a dose-dense schedule of rituximab plus CHOP Ann. Onc., January 1, 2006; 17(1): 176 - 177. [Full Text] [PDF] N. U. Lin, R. Gelman, and E. P. Winer Dose Density in Breast Cancer: A Simple Message? J Natl Cancer Inst, December 7, 2005; 97(23): 1712 - 1714. [Full Text] [PDF] S.-T. Lim, R. Karim, A. Tulpule, B. N. Nathwani, and A. M. Levine Prognostic Factors in HIV-Related Diffuse Large-Cell Lymphoma: Before Versus After Highly Active Antiretroviral Therapy J. Clin. Oncol., November 20, 2005; 23(33): 8477 - 8482. [Abstract] [Full Text] [PDF] B. Coiffier State-of-the-Art Therapeutics: Diffuse Large B-Cell Lymphoma J. Clin. Oncol., September 10, 2005; 23(26): 6387 - 6393. [Abstract] [Full Text] [PDF] S. A. Gregory and L. Trumper Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes? Ann. Onc., September 1, 2005; 16(9): 1413 - 1424. [Abstract] [Full Text] [PDF] J. S. Abramson and M. A. Shipp Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach Blood, August 15, 2005; 106(4): 1164 - 1174. [Abstract] [Full Text] [PDF] J. K. Doorduijn and P. Sonneveld In Reply: J. Clin. Oncol., July 20, 2005; 23(21): 4799 - 4799. [Full Text] [PDF] P. Feugier, A. Van Hoof, C. Sebban, P. Solal-Celigny, R. Bouabdallah, C. Ferme, B. Christian, E. Lepage, H. Tilly, F. Morschhauser, et al. Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte J. Clin. Oncol., June 20, 2005; 23(18): 4117 - 4126. [Abstract] [Full Text] [PDF] T. Kober, J. Bohlius, S. Trelle, and A. Engert Second Biannual Report of the Cochrane Haematological Malignancies Group J Natl Cancer Inst, April 6, 2005; 97(7): E1 - E. [Full Text] J. W. Sweetenham Diffuse Large B-Cell Lymphoma: Risk Stratification and Management of Relapsed Disease Hematology, January 1, 2005; 2005(1): 252 - 259. [Abstract] [Full Text] [PDF] G. H. Lyman, D. C. Dale, J. Friedberg, J. Crawford, and R. I. Fisher Incidence and Predictors of Low Chemotherapy Dose-Intensity in Aggressive Non-Hodgkin's Lymphoma: A Nationwide Study J. Clin. Oncol., November 1, 2004; 22(21): 4302 - 4311. [Abstract] [Full Text] [PDF] C. Engel, M. Scholz, and M. Loeffler A computational model of human granulopoiesis to simulate the hematotoxic effects of multicycle polychemotherapy Blood, October 15, 2004; 104(8): 2323 - 2331. [Abstract] [Full Text] [PDF] B. Coiffier, G. Salles, M. Pfreundschuh, and M. Loeffler Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma Blood, September 1, 2004; 104(5): 1584 - 1586. [Full Text] [PDF] M. Pfreundschuh, L. Trumper, M. Kloess, R. Schmits, A. C. Feller, C. Rudolph, M. Reiser, D. K. Hossfeld, B. Metzner, D. Hasenclever, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL Blood, August 1, 2004; 104(3): 626 - 633. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020